WO2015190555A1 - 多重同種抗原ペプチド - Google Patents
多重同種抗原ペプチド Download PDFInfo
- Publication number
- WO2015190555A1 WO2015190555A1 PCT/JP2015/066865 JP2015066865W WO2015190555A1 WO 2015190555 A1 WO2015190555 A1 WO 2015190555A1 JP 2015066865 W JP2015066865 W JP 2015066865W WO 2015190555 A1 WO2015190555 A1 WO 2015190555A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- map
- cell
- antibody
- antigen
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 232
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 159
- 230000016784 immunoglobulin production Effects 0.000 claims abstract description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 claims abstract description 38
- 125000006850 spacer group Chemical group 0.000 claims abstract description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 8
- 230000005859 cell recognition Effects 0.000 claims description 93
- 239000000427 antigen Substances 0.000 claims description 79
- 102000036639 antigens Human genes 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 59
- 230000000961 alloantigen Effects 0.000 claims description 33
- 125000000524 functional group Chemical group 0.000 claims description 27
- 239000000411 inducer Substances 0.000 claims description 26
- 108010074328 Interferon-gamma Proteins 0.000 claims description 22
- 102000008070 Interferon-gamma Human genes 0.000 claims description 22
- 229960003130 interferon gamma Drugs 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 238000009739 binding Methods 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000014828 interferon-gamma production Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 238000009448 modified atmosphere packaging Methods 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 27
- 241000282472 Canis lupus familiaris Species 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000013566 allergen Substances 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 241000282465 Canis Species 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000003630 histaminocyte Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 108091008875 B cell receptors Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 210000002443 helper t lymphocyte Anatomy 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 229940037003 alum Drugs 0.000 description 6
- 229940125644 antibody drug Drugs 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 5
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 4
- 208000032163 Emerging Communicable disease Diseases 0.000 description 4
- 238000005873 Huisgen reaction Methods 0.000 description 4
- 241000282373 Panthera pardus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229910001431 copper ion Inorganic materials 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000036647 reaction Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 2
- -1 CD11 Proteins 0.000 description 2
- 108010065524 CD52 Antigen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 108010041012 Integrin alpha4 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000023750 transforming growth factor beta production Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- XBDIERREJVJZHO-UHFFFAOYSA-N CC(CCCCNC(CCS)=O)C(N)=O Chemical compound CC(CCCCNC(CCS)=O)C(N)=O XBDIERREJVJZHO-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960002235 anthrax antigen Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Definitions
- the present invention relates to a multiple alloantigen peptide and an antibody production inducer containing the same, a method for producing the peptide, and a method for producing an antibody using the peptide.
- Antibodies bind to foreign substances such as viruses and bacteria in the body and self-antigens such as cancer cells and play a major role in immune reactions that eliminate them from the body. Therefore, a method for artificially and efficiently inducing antibody production in the body for these substances that are subject to antibody reaction can be greatly utilized as a treatment or prevention method for infectious diseases and cancer.
- a method for efficiently producing antibodies against any antigen there is currently no method for efficiently producing antibodies against any antigen, and there are still many infectious diseases and cancers that cannot be dealt with.
- T cell reaction In order to differentiate B cells into plasma cells in the body to produce class-switched antibodies, antigen recognition by T cells must first be performed. That is, the target antibody production does not occur unless a T cell reaction occurs. Since this T cell reaction depends on the antigen recognition pattern of the T cell receptor, the T cell reaction does not occur to an antigen that does not apply to it (referred to as T cell restriction). For example, it is difficult to induce antibodies against cancer antigens whose differences from self-antigens are unclear in cancer immunotherapy and the like, but the possibility of B cell self-antigen recognition remains slight. This is because T cells having a T cell receptor that recognizes a cancer antigen as a part are excluded in the thymus and thus do not exist in the body.
- vaccines against infectious diseases can be prepared by preparing pathogens.
- vaccines cannot be developed unless a culture system for preparing a large amount of pathogens is established.
- it is difficult to cope with emerging infectious diseases with conventional vaccine development methods using a large-scale culture system of pathogens, and even if it can be handled, it takes a considerable number of years to construct the system. To do.
- the pathogen frequently mutates quickly, that is, in the case of pathogens having so-called antigenic gene polymorphism, it takes time to establish a new large-scale culture method. There is a problem that manufacturing cannot keep up.
- the MAP peptide has, for example, a conjugate containing a plurality of lysine (Lys), which is one of amino acids, and, optionally, cysteine (Cys), in the case of Lys, its ⁇ -amino group and ⁇ -amino group, or Cys
- the peptide can be obtained by binding a peptide (a part of an antigen recognized by a cell) to a sulfhydryl group.
- Patent Document 1 uses MAP against S. pneumoniae. Specifically, it is described that MAP-4 structures having a total of four peptides were prepared by selecting two positions from the antigenic peptide of Pneumococcus pneumoniae and alternately alternating these two types of peptides.
- Patent Document 2 describes a multi-antigen peptide that binds T cell epitopes and can induce both a humoral immune response and a cytotoxic T lymphocyte immune response.
- Non-Patent Document 1 discloses that a B cell epitope (a peptide site that is easily recognized by a membrane cell antibody on the surface of a B cell), and a T cell epitope (T cell (Peptide site to be recognized) was prepared as a synthetic peptide, and the increase in antibody titer was examined by administering MAP bound to them together with an adjuvant to mice and rabbits, and MAP (MAP-8 bound with 8 B cell epitopes) ) Showed no increase in antibody titer, but MAP (MAP-4) in which B cell epitope and T cell epitope were mixed had an increase in antibody titer.
- MAP MAP-8 bound with 8 B cell epitopes
- Non-Patent Document 2 describes that MAP in which T cell epitopes against malaria parasites are combined, MAP in which T cell epitopes and B cell epitopes are mixed, and antibody induction is confirmed.
- Non-Patent Document 3 uses MAP (MAP-4) that binds four epitopes of anthrax antigen together with Freund's adjuvant, and uses a rabbit that can recognize the epitope as a T cell epitope as a subject of administration. It is described that it was confirmed in rabbits that the neutralizing antibody titer was increased by recognizing antigens.
- the said epitope is a site
- B cells In order for B cells to differentiate into plasma cells and produce class-switched antibodies, 1) the antigen is taken into the B cells via the B cell receptor (the membrane-type antibody on the surface of the B cell), and 2) B The cell presents a part of the antigen (T cell epitope) digested intracellularly to the helper T cell. 3) The helper T cell recognizes and activates it to produce a cytokine, and the antigen-presenting B cell A series of processes of stimulating in reverse was considered essential. Therefore, restriction on the type of T cell epitope necessary for antigen recognition by helper T cells also becomes a restriction on antibody production.
- B cell receptor the membrane-type antibody on the surface of the B cell
- an object of the present invention is to provide an immunostimulation method, so-called vaccine, that can induce the production of a target antibody in the body by directly stimulating B cells without being restricted by antigen recognition by T cells. That is.
- the present inventors have used T-cells that recognize the peptide with an adjuvant or the like by using a multi-layer artificial peptide having the same type of B-cell recognition peptide. It has been found that even without forcible induction in the body, B-cells in vivo are directly stimulated in the absence of T cell epitopes to induce class-switched antibody production.
- an artificial peptide having such a structure can produce an antibody even in the absence of a T cell epitope, production of the antibody against the peptide can be easily induced by using the peptide.
- the present invention includes the following features.
- a multiple alloantigen peptide comprising a dendritic core and a B cell recognition peptide, comprising 4 to 8 homologous B cell recognition peptides linked directly or via a spacer to the end of the dendritic core
- a multiple alloantigen peptide characterized by directly stimulating B cells in vivo in the absence of a T cell epitope to induce class switched antibody production.
- the antibody production inducer according to any one of (7) to (10), which is used for treatment or prevention of a disease.
- a pharmaceutical composition comprising the antibody production inducer according to any one of (7) to (12) above.
- a method for producing an antibody comprising the following step (a).
- step B A step of collecting a biological sample containing B cells producing an antibody that binds to a B cell recognition peptide of the multiple alloantigen peptide from an administration subject.
- C The B cells are extracted from the biological sample collected in step (b).
- D step of culturing the B cell and recovering the antibody (19) from the biological sample collected from the subject administered with the multiple alloantigen peptide according to (1) above, A method of screening for an antibody that binds to a B cell recognition peptide.
- (21) A method for producing an IgG antibody for inhibiting IgE production, which recognizes allergens, comprising the following steps (a ′′) and (b ′′).
- (A ′′) a step of administering to the subject the multiple antigen peptide according to any one of the above (1) to (6) comprising a B cell recognition peptide comprising a part of the structure of the allergen (b ′′) the administered subject Collecting a biological sample from the sample and collecting an IgG antibody that recognizes allergen (22) The subject obtained by administering to the subject the multiple alloantigen peptide according to any of (1) to (6) above A method for identifying the gene sequence of an antibody antigen recognition site or the amino acid sequence of an antibody antigen recognition site from antibody-producing B cells.
- antibody production in the body is possible without being restricted by antigen recognition of T cells, so that the success rate of antibody production, particularly the success of antibody production against self-antigens, compared to conventional antibody production techniques. The rate is improved.
- Antibody production by the multiple alloantigen peptides of the present invention can be used for the treatment and / or prevention of diseases.
- antibody drug preparations are foreign substances even when viewed from the body, even though they are human antibodies, and eventually the neutralization antibody against the antibody drug preparations is acquired in the body as the number of administrations increases, and the action of the antibody drug is reduced.
- this is not the case with the antibody induction according to the present invention, and the production of the target antibody can be stimulated each time it is inoculated.
- This figure exemplarily shows the structure of MAP peptides (MAP-2, MAP-4, MAP-8 and MAP-16).
- This figure shows that each MAP peptide (Group 1 to Group 4) or physiological salt intended to select MAP-2, MAP-4, MAP-8 and MAP-16 having a high antibody induction ability
- This figure shows MAP-4 (Group 1 to Group 4), MAP-8 (Group 5 to Group 8) in order to determine the optimal dose for antibody induction by changing the dose of MAP-4 and MAP-8.
- MAP-4 Group 1 to Group 4
- MAP-8 Group 5 to Group 8
- administration / blood collection schedule A
- Balb / c mice female, 6 weeks old
- mouse IgE mouse IgE
- dog IgE dog IgE
- This figure shows the time course of OD-8-specific IgE (OD 450 nm) when MAP-8 was administered intravenously together with Alum adjuvant to dogs sensitized with Drosophila mite antigen (allergen).
- treated dogs are 12-35 ( ⁇ ) and 12-36 ( ⁇ )
- negative control dogs administered with physiological saline are 12-15 ( ⁇ ).
- This figure shows the ratio of M. leopard mite IgE values when MAP-8 was administered intravenously with alum adjuvant to dogs sensitized with M. leopard mite antigen (allergen).
- the IgE value at the time of allergen administration was set to 1.0.
- the treated dogs are 12-35 ( ⁇ ) and 12-36 ( ⁇ ), and the negative control dogs administered with physiological saline are 12-15 ( ⁇ ).
- the present invention relates to a multiple alloantigen peptide comprising a dendritic core and a B cell recognition peptide, wherein 4 to 4 are bound to the end of the dendritic core directly or via a spacer.
- a multiple alloantigen peptide comprising 8 homologous B cell recognition peptides and characterized by directly stimulating in vivo B cells in the absence of a T cell epitope to induce class switched antibody production provide.
- MAP multiple alloantigen peptide
- MAP multiple alloantigen peptide
- a dendritic core having a dendritic macromolecular (ie, dendrimer) structure and a dendritic end of the core directly or via a spacer. And a plurality of the same kind of B cell recognition peptides bound together.
- the dendritic core is a dendritic support core for binding a plurality of B cell recognition peptides (hereinafter also referred to as “antigen peptides” for convenience), preferably 4-8.
- the dendritic core may be of a generally known structure, and the dendritic polymer is preferably selected based on two or more identical branches originating from a core molecule having at least two functional groups. Good.
- the dendritic core is also called a dendritic polymer, and examples thereof include, but are not limited to, structures described in US Pat. No. 4,289,872, US Pat. No. 4,515,920 and the like.
- a peptide containing a plurality of lysine residues (K) is preferred.
- the peptide containing the lysine residue may further contain a cysteine residue (C).
- C cysteine residue
- a cysteine residue C
- a recognition peptide can be attached.
- a maximum of 4 B cell recognition peptides can be bound.
- a spacer may be bound to the lysine residue (K) via its ⁇ -carboxyl group.
- the spacer is preferably a peptide composed of 2 or more and 10 or less amino acid residues, for example, KKC, K- ⁇ A-C (where ⁇ A represents a ⁇ -alanine residue, and C represents cysteine Represents a residue).
- K lysine residue
- the N-terminal amino acid group of the spacer has a maximum of 4 B cell recognition peptides similar to those described above bound through the ⁇ -amino group. Structures can be linked. In this case, the generated MAP has up to 8 B cell recognition peptides.
- the B cell recognition peptide is an antigen segment that is recognized by the B cell receptor and determines antigenicity.
- the B cell recognition peptide is any seven or more amino acids selected from the amino acid sequence information of the target protein, and is preferably a continuous peptide (linear epitope) on the protein surface.
- the B cell recognition peptide may be a peptide constituting the three-dimensional structure of the protein recognized by the B cell receptor. For example, a discontinuous combination (conformational epitope) of peptides adjacent to each other on the protein surface is selected. May be.
- a linear epitope is a continuous linear epitope of a primary amino acid sequence in a specific region of an antigen protein, and specifically binds to an antibody against the epitope.
- the conformational epitope is, for example, a combination of peptides constituting each of two or more conformations adjacent to each other on the protein surface. These peptides exist discontinuously in the primary amino acid sequence of a specific region of the antigen protein. A combination of two or more peptides having such a correspondence relationship becomes a conformational epitope, and an antibody against the epitope specifically recognizes and binds to the higher-order structure of the antigen protein.
- the B cell recognition peptide can also be called a B cell epitope in terms of an antigen segment that is recognized by a B cell receptor and determines antigenicity.
- the B cell recognition peptide may be referred to as “B cell epitope” for convenience.
- B cell recognition peptides are generally T cell non-mediated, since they are often different from T cell epitopes, which refer to antigenic moieties that bind to T cell receptors and are recognized by T cells.
- TCR T cell receptor
- the B cell recognition peptide contributes to the antibody production process by binding to the B cell receptor (BCR) without being presented as an antigen to the TCR, and thus is involved only in humoral immunity.
- the B cell recognition peptide typically has an amino acid sequence consisting of 7 to 50 amino acids, preferably 10 to 20 amino acids, more preferably 12 to 16 amino acids.
- the B cell recognition peptide preferably corresponds to a portion exposed on the surface of a protein (including metabolites in vivo). Therefore, the B cell recognition peptide can be arbitrarily exposed to the surface of a biopolymer such as a protein by those skilled in the art based on the analysis result or prediction result on information such as the amino acid sequence and three-dimensional structure of the protein to be recognized by the antibody. It is possible to design by selecting the part that has been. For example, various prediction methods may be used as a known technique. For example, Julia V. Ponomarenko and Marc HV van Regenmortel, “B-Cell Epitope Prediction” (Jenny Gu and Philip E.
- ⁇ ⁇ Sequence-based methods are limited to predicting continuous epitopes. Most of this method is based on the assumption that the epitope needs to be accessible for binding to the antibody. This method is therefore based on the use of epitope properties associated with surface exposure.
- the score of a specific amino acid residue in a predetermined protein sequence is calculated by a computer using the amino acid scale.
- the final score for this residue is the average of the scale values for the number of amino acids in Windows.
- ABC pred method using artificial neural network S. Saha and GP Raghava, Proteins 2006, 65 (1): 40-48
- BepiPred method based on the combination of hidden Markov model and two amino acid scale JE Larsen et al., Immunome Res., 2006, 2: 2.
- the structure-based method is a method based on the three-dimensional structure of an antigen, and two methods, namely CEP (U. Kulkarni-Kale et al., Nucleic Acids Res 33: W168-W171) and DiscoTope (PH Andersen et al. , 2006, Protein Sci 15 (11): 2558-2567).
- protein-protein binding site prediction methods include the PPI-PRED method (J.R. Bradford et al., Bioinformatics 2005, 21 (8): 1487-1494).
- a class-switched antibody that recognizes the epitope only by designing a single epitope (preferably an antigen) Specific IgG) production can be induced.
- the B cell recognition peptide of the present invention can be selected from sites that cannot normally become B cell epitopes in nature, in addition to peptide sites that become existing B cell epitopes. Thereby, in addition to the existing B cell epitope, it is possible to artificially induce a new B cell epitope, and the inhibitory signal involving IgG against the new B cell epitope recognizes the conventional B cell epitope.
- Memory B cells having membrane-type IgG on the cell surface and mast cells having similar IgE on the cell surface can be used. This enables treatment of autoimmune diseases by suppressing existing antibody-producing B cells and allergy treatment by suppressing mast cell degranulation.
- the B cell recognition peptide is bound to the end of the dendritic core directly or via a spacer (preferably, one is covalently bound to each end).
- a functionalized solid-state resin can be bound to a functionalized dendritic core, and a reactive functional group of a B cell recognition peptide can be bound to this reactive functional group at the dendritic end (W kowalczyk et al., J. Pep. Sci. 2011, 17: 247-251).
- the B cell recognition peptide can be synthesized by a known technique such as an automatic peptide synthesizer based on a predetermined amino acid sequence (JM Stewart and JD Young, Solid Phase Peptide Synthesis, 2 nd ed., Pierce Chemical Company, 1984, GB Fields et al., Principles and Practice of Peptide Synthesis, in GA Grant (ed): Synthetic Peptides: A User's Guide, WH Freeman, 1992).
- a known technique such as an automatic peptide synthesizer based on a predetermined amino acid sequence
- the MAP of the present invention includes a plurality of B cell recognition peptides, preferably 4 to 8, and the peptides have the same or high identity.
- the peptide may be a known B cell epitope or a completely new epitope.
- the “same type of B cell recognition peptide” means a peptide having the same property as an epitope and having a high identity.
- “Peptide having high identity” refers to a sequence identity with the peptide of 85% or more, preferably 90% or more, based on any one B cell recognition peptide among a plurality of B cell recognition peptides.
- the number of amino acids in the amino acid sequence of the peptide is 1 to 4 differences, preferably 1 to 3 differences, more preferably 1 to 2 Peptides with differences, more preferably with one difference.
- the same property as an epitope refers to the property that the production of an antibody capable of binding to a target protein or polypeptide of interest can be induced in vivo.
- difference with respect to amino acids means a difference in the number of amino acids due to amino acid substitution, deletion or addition.
- the B cell recognition peptide is a peptide derived from either a self antigen or a non-self antigen, preferably a self antigen.
- autoantigen means a gene product common to the same species as the subject to which the MAP of the present invention is administered or a metabolite derived from the gene product, and is homologous and allogeneic. Refers to both. Therefore, a B cell recognition peptide can be designed based on known genetic information in the same species as the administration subject without reading individual genetic information in the administration subject. Even if the same gene product has different amino acid sequences in each subject due to mutations such as single nucleotide polymorphisms, the MAP of the present invention may be designed and administered based on individual genetic information possessed by each subject. In this case, the design is individually optimized, but versatility is lost.
- the B cell recognition peptide based on the information is also a peptide derived from “self antigen”.
- the antibody induced by the present invention is an autoantibody.
- gene products include, but are not limited to, antibodies, cytokines, growth factors, transmembrane proteins, and cell surface proteins. Further, antigens derived from tumor cells, antigens such as tumor-producing factors, and factors derived from self gene products directly or indirectly related to diseases are all included as autoantigens in the present specification.
- the MAP of the present invention having an IgE-derived B cell recognition peptide can be used for the treatment or prevention of allergic diseases such as asthma, hay fever and food allergy.
- cytokines include, but are not limited to, TNF ⁇ and IL-1 ⁇ .
- the MAP of the present invention having a B cell recognition peptide derived from TNF ⁇ can be used for treatment or prevention of rheumatoid arthritis.
- the MAP of the present invention having an IL-1 ⁇ -derived B cell recognition peptide can be used for the treatment or prevention of cryopyrin-related periodic syndrome.
- growth factors include, but are not limited to, vascular endothelial growth factor (VEGF).
- VEGF vascular endothelial growth factor
- the MAP of the present invention having a VEGF-derived B cell recognition peptide can be used for the treatment or prevention of cancer such as colorectal cancer or age-related macular degeneration.
- transmembrane protein examples include epidermal growth factor receptor (EGFR), receptor activator of nuclear factor-excellentB ligand (RANKL), ⁇ 4 integrin, CD2, CD3, CD11, CD20, CD25, CD30, CD33, CD52 and CD152 (CTLA4) can be mentioned, but not limited to these.
- EGFR epidermal growth factor receptor
- RTKL receptor activator of nuclear factor-excellentB ligand
- CTLA4 integrin CD2, CD3, CD11, CD20, CD25, CD30, CD33, CD52 and CD152
- CTLA4 integrin CD2, CD3, CD11, CD20, CD25, CD30, CD33, CD52 and CD152
- CTLA4 integrin CD2, CD3, CD11, CD20, CD25, CD30, CD33, CD52 and CD152
- CTLA4 integrin CD2, CD3, CD11, CD20, CD25, CD30, CD33, CD52 and CD152
- CTLA4 integrin CD2, CD3, CD11, CD20,
- the MAP of the present invention having a B cell recognition peptide derived from ⁇ 4 integrin can be used for the treatment or prevention of multiple sclerosis.
- the MAP of the present invention having a CD2-derived B cell recognition peptide can be used for the treatment or prevention of psoriasis vulgaris.
- the MAP of the present invention having a CD3-derived B cell recognition peptide can be used for the treatment or prevention of acute rejection.
- the MAP of the present invention having a CD11-derived B cell recognition peptide can be used for the treatment or prevention of psoriasis vulgaris.
- the MAP of the present invention having a CD20-derived B cell recognition peptide can be used for the treatment or prevention of cancers such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- the MAP of the present invention having a CD25-derived B cell recognition peptide can be used for the treatment or prevention of acute rejection.
- the MAP of the present invention having a CD30-derived B cell recognition peptide can be used for the treatment or prevention of cancers such as Hodgkin lymphoma.
- the MAP of the present invention having a CD33-derived B cell recognition peptide can be used for the treatment or prevention of cancer such as acute myeloid leukemia.
- the MAP of the present invention having a CD52-derived B cell recognition peptide can be used for the treatment or prevention of cancer such as B cell chronic lymphocytic leukemia.
- the MAP of the present invention having a CD152-derived B cell recognition peptide can be used for the treatment or prevention of cancer such as melanoma.
- cell surface proteins include, but are not limited to, HER2.
- the MAP of the present invention having a HER2-derived B cell recognition peptide can be used for treatment or prevention of cancer such as breast cancer.
- non-self antigen means an epitope contained in a gene product that is not commonly used in the same species as the subject to which the MAP of the present invention is administered or a metabolite derived from the gene product. Refers to a foreign body for the same species as the subject or subject to be administered. Examples of such non-self antigens include antigens derived from pathogens such as bacteria and viruses. According to the present invention, a MAP can be designed and produced simply by selecting a peptide that can be any one epitope when the structure of a target pathogen becomes clear. Therefore, there is no need to establish a pathogen culture method.
- IgG that recognizes this novel B cell epitope can bind to the IgG receptor of B cells and mast cells while binding to the antigen in the body. This can be used as a therapeutic or prophylactic agent to suppress allergic symptoms depending on the mechanism of immunogen crime.
- the B cell has a membrane-type antibody that recognizes the same antigen, and the IgE that recognizes the same antigen is bound to the surface of the mast cell, the antibody that recognizes the new B cell epitope is the B cell. Since it binds to the IgG receptor on the surface of mast cells, it is possible to send a signal that suppresses activation to these B cells and mast cells. B cells containing an activation suppression signal cannot be activated and cannot produce antibodies. Therefore, this action can be used as a therapeutic or prophylactic agent that suppresses autoantibody-producing B cells. Similarly, since mast cells cannot be degranulated, they can be used for therapeutic or prophylactic drugs that suppress allergic symptoms.
- subjects to be administered multiple alloantigen peptides include humans, livestock animals (eg, cattle, pigs, poultry, camels, etc.), pets Mammals (for example, dogs, cats, birds, etc.), competing animals (eg, horses, etc.), and ornamental animals bred at the zoo are included, preferably humans.
- livestock animals eg, cattle, pigs, poultry, camels, etc.
- pets Mammals for example, dogs, cats, birds, etc.
- competing animals eg, horses, etc.
- ornamental animals bred at the zoo are included, preferably humans.
- the MAP induces antibody production that is class-switched in a T-cell-independent manner in the body of the subject.
- T cell non-mediated refers to the normal immune system that directs cellular and humoral immunity by binding to a T cell receptor, such as a T cell epitope, It means to induce antibody production against MAP by directly acting on B cell receptor.
- the antibody produced by the present invention is IgG, IgA, or IgE, preferably IgG. It is important that IgG production can be induced in a T cell-independent manner. In general, when a foreign body enters the body, IgM antibodies are produced within the first approximately one week and the initial in vivo defense functions. However, IgM has a short half-life and is in the blood in about one week to 10 days. The antibody titer decreases. As T cells that react to foreign substances gradually become active in the body with a delay in IgM production, interferon ⁇ is normally produced from T cells, so that IgG antibodies are produced and protection by humoral immunity is achieved. It will be strengthened.
- the B cell recognition peptide of the present invention is a peptide site recognized by a B cell, that is, a known B cell epitope or a novel B cell epitope. Since the B cell recognition peptide is T cell non-mediated, it has been said that an immunoglobulin class switch from IgM to IgG does not occur in the case of such an epitope, but it is nonspecifically produced in the body. It has now been shown that B cells stimulated by MAP under the stimulation of typical interferon gamma can produce IgG. Therefore, when MAP is administered to a subject, administration with interferon ⁇ or a substance that induces interferon ⁇ ensures that B cells produce IgG.
- the MAP of the present invention has a structure as shown in FIG. 1, for example, but 4 to 8 homologous B cell recognition peptides as shown in MAP-4 and MAP-8, preferably the same B cell recognition It has a dendritic structure containing a peptide. Examples of MAP production are shown below. 2.
- the present invention provides a method for producing MAP as described above, comprising the following steps (1) to (4): (1) preparing a dendritic core having a reactive functional group; (2) preparing a plurality of the same kind of B cell recognition peptides having a reactive functional group, (3) a step of binding the reactive functional group of the dendritic core and the reactive functional group of each of the B cell recognition peptides to produce a multiple antigen peptide, and (4) a step of recovering the multiple antigen peptide.
- steps (1) to (4) (1) preparing a dendritic core having a reactive functional group; (2) preparing a plurality of the same kind of B cell recognition peptides having a reactive functional group, (3) a step of binding the reactive functional group of the dendritic core and the reactive functional group of each of the B cell recognition peptides to produce a multiple antigen peptide, and (4) a step of recovering the multiple antigen peptide.
- the dendritic core is, as explained above, a dendritic support for binding a plurality of homologous B cell recognition peptides, preferably 4-8 homologous (preferably identical) B cell recognition peptides. Is the core.
- the dendritic core may have a commonly known structure, may include multiple lysine residues (K), and may further include a cysteine residue (C).
- K multiple lysine residues
- C cysteine residue
- FIG. 1 portions other than 4 to 8 B cell recognition peptides (B cell epitopes) are formed so as to illustrate the structure of the MAP of the present invention (preferably a structure such as MAP-4 and MAP-8). It is the dendritic core that does.
- the dendritic core may include, for example, a KK sequence
- MAP-8 it may include, for example, a KKKK sequence.
- a spacer is usually bound to the central K of these sequences.
- the spacer is preferably a peptide composed of two or more amino acid residues, such as KK, K- ⁇ A-C (where ⁇ A represents a ⁇ -alanine residue), and the like. It is not limited to these. It is designed so that two B cell recognition peptides per K can bind to the left and right K or KK other than the central K.
- the terminal of the dendritic core can have an appropriate functional group for binding to the B cell recognition peptide.
- the functional group may be any functional group that can be used for protein modification, and examples thereof include an amino group, a sulfhydryl group, an acetylene group, and an N-hydroxysuccinimidyl group.
- the functional group on the side of one B cell recognition peptide is any functional group capable of binding reaction with the terminal functional group of the dendritic core, for example, N-hydroxysuccinimidyl group for amino group, sulfhydryl group for sulfhydryl group. Or a carboxyl group, an azide group with respect to an acetylene group, etc.
- the B cell recognition peptide is as described above.
- the dendritic core having the KK sequence has the following structure in which the terminal functional group has an acetylene group:
- the terminal functional group of the B cell recognition peptide having the above structure is an azide group.
- the binding reaction in this case is a Huisgen reaction.
- This reaction is a reaction in which an alkyne and an azide are combined using a monovalent copper ion as a catalyst.
- the reaction product is considered to be stable and has little side reaction, and is attracting attention as a click chemistry.
- the copper ion catalyst solution can be prepared using an aqueous copper sulfate pentahydrate solution and ascorbic acid. A specific example of this reaction is described in Example 2 below.
- the peptide recovery method may be a general protein or polypeptide purification method such as gel filtration chromatography, ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography, affinity chromatography, high performance liquid chromatography. Chromatography such as chromatography (HPLC) can be performed alone or in combination.
- the object can be identified by nuclear magnetic resonance spectrum analysis NMR, mass spectrum analysis, amino acid analysis, or the like.
- the present invention further provides an antibody production inducing agent comprising the above MAP according to the third aspect.
- the antibody production inducer of the present invention is a preparation that induces T-cell-independent class-switched antibody production.
- the antibody production inducer of the present invention can be used as a pharmaceutical composition for the treatment of diseases or the prevention of diseases by remarkably inducing the production of antibodies, and is used as a “vaccine” for the purpose of treatment and / or prevention can do.
- the antibody production inducers of the present invention can be classified as shown in the following (a), (b) and (c).
- the antibody production inducer of the present invention can induce antibodies against tumor antigens.
- (C) Antibody production inducer capable of dealing with foreign substances The present invention can be said to be a method that can easily induce the production of desired antibodies against foreign substances by chemical synthesis. It is possible to artificially induce antibodies in places where it is difficult to produce antibodies with conventional techniques. Specifically, in the conventional method against influenza virus, only a vaccine that induces an antibody only at a highly antigenic site where mutation is likely to occur was obtained. It is possible to induce antibody production strongly.
- the safety and effectiveness of human preparations are determined by animal experiments by selecting peptide sites whose amino acid sequences are homologous or highly identical in proteins or polypeptides that are highly conserved in humans and non-human animals. Sexual security can be taken directly.
- the use of the present invention can be derived not only for human body medicine but also for animal medicine, and can be said to have a wide range of applications.
- the preparation can be prepared when the structure of the target pathogen is clarified. Since it is chemical synthesis, it is not necessary to establish a method for culturing pathogens. Moreover, since antibody production can be forcibly induced in B cells, a peptide sequence serving as an antigen recognition site can be freely set. These can be used to develop vaccines against emerging infectious diseases and vaccines that induce antibodies at constant sites that do not mutate against viruses that frequently mutate. For example, it is possible to deal with viral diseases that cannot be dealt with by the prior art such as West Nile virus, Ebola hemorrhagic fever, influenza, foot-and-mouth disease.
- the preparation can be prepared when the structure of the target pathogen is clarified, if the antigenic mutation is clarified, the peptide can be designed in the same manner for the mutation. It is of course possible to prepare the antibody production inducer of the invention.
- the present inventors considered a multiple antigen structure as a T cell-independent antigen.
- a peptide to be antibody-induced is prepared by chemical synthesis, and two to sixteen synthetic peptides (MAP-2 to MAP-16) are prepared by chemical synthesis.
- IgE was selected as a molecule to be antibody-induced, and a site with high identity in human, mouse, and dog was selected in the CH3 region. This was administered to mice and dogs to examine the extent of autoantibody elevation. First, the number of peptides that bind to MAP was examined, and an increase in antibody was observed against MAP-4 and MAP-8. Therefore, the number of peptides required to obtain the effects of the present invention is 4 to 8 It was decided.
- An effective amount of a MAP of the present invention in humans is, but not limited to, about 0.05 to 2.5 ⁇ g / kg body weight to 1 mg to 10 mg / kg body weight for MAP-4 as a single dose, From 0.5 to 25.0 ⁇ g / kg body weight to 1 mg to 10 mg / kg body weight.
- the dose can be appropriately changed depending on the body weight, age, sex, symptom, type of disease, severity, administration method, etc. of subjects including humans.
- the isotype of the antibody that rises independent of T cells according to the present invention is preferably IgG.
- This IgG induction is thought to be due to the action of interferon ⁇ produced from T cells in a non-antigen-specific manner.
- MAP-4 and interferon ⁇ were transferred to mice that did not have T cells (nude mice). It was confirmed that T cell-independent antibody (IgG) production was caused by antigen-nonspecific interferon ⁇ . Therefore, the antibody production inducer of the present invention preferably contains interferon ⁇ .
- the forms of the antibody production inducer of the present invention are, for example, solutions, suspensions, tablets, injections, granules, emulsifiers, etc., excipients, diluents, binders, flavoring agents, surfactants, etc. These additives can be appropriately included.
- An adjuvant is basically unnecessary as long as production of interferon ⁇ is confirmed in the administration subject, but it is added as necessary.
- the antibody production inducer of the present invention preferably contains interferon ⁇ or an adjuvant having the ability to produce interferon ⁇ .
- the adjuvant having the ability to produce interferon ⁇ is not particularly limited, and examples thereof include ⁇ -galactosylceramide, ⁇ -galactosylceramide analogs, CpG which is a bacterial oligonucleotide, aluminum hydroxide (alum; Alum), and the like.
- Examples of the ⁇ -galactosylceramide analog include, for example, International Publication WO 2007/099999 (US Pat. No. 8,163,705), International Publication WO 2009/1199692 (US Pat. No. 8,551,959), International Publication WO 2008/102888 (US Pat.
- the adjuvant is a beta-type transforming growth factor (TGF- ⁇ ) or a substance that induces TGF- ⁇ production predominantly.
- TGF- ⁇ beta-type transforming growth factor
- the substance that induces TGF- ⁇ production is not particularly limited, and examples thereof include cholera toxin subunit B and retinoic acid.
- IgE is produced predominantly, it is a cytokine such as interleukin-4 and interleukin-13 or a substance that induces production of the cytokine predominantly.
- Substances that induce cytokine production such as interleukin-4 and interleukin-13 are not particularly limited, and examples include forskolin and Derp1 (main tick allergen).
- cytokines such as interferon ⁇ , TGF- ⁇ , interleukin-4, and interleukin-13 are produced but not any of them are produced, it is not preferable as the effect of the present invention.
- the antibody production-inducing agent of the present invention is used as a pharmaceutical composition for the above-mentioned allergic diseases, proliferative diseases such as cancer, bone diseases, age-related macular degeneration, multiple sclerosis, psoriasis vulgaris, infectious diseases, etc. Can be used for the prevention or treatment of. That is, according to this invention, the pharmaceutical composition containing said antibody production inducer is also provided.
- the present invention further provides a method for preventing or treating the above diseases, which comprises administering the above MAP or the above antibody production inducer to a subject.
- the production of antibodies is the production of T-cell mediated class-switched antibodies, particularly including the production of T-cell mediated IgG antibodies, IgA antibodies, or IgE antibodies, preferably IgG Antibody production. Since the peptide to be bound to MAP can be freely set without being bound by the known B cell epitope sequence, it is theoretically possible to induce the antibody desired by the practitioner in the body.
- the production of the antibody in the method of the present invention can be performed for the purpose of disease treatment or disease prevention.
- Administration routes include intravenous administration, transmucosal administration, rectal administration, subcutaneous administration, intramuscular administration, and oral administration, but are not limited thereto.
- the present invention further provides a method for producing a target antibody, which includes the step (a) of administering the MAP of the present invention to a subject.
- This method further includes a step (b) of collecting a biological sample containing B cells producing an antibody that binds to a B cell recognition peptide contained in the MAP from an administration subject; the B sample collected from the biological sample collected in step (b); A step (c) of selecting cells; and a step (d) of recovering the antibody by culturing the B cells.
- the present invention further provides a method for screening an antibody that binds to a B cell recognition peptide contained in the MAP from a biological sample collected from a subject administered with the MAP of the present invention.
- Another embodiment includes a method of recovering an antibody that binds to a B cell recognition peptide contained in the MAP from a biological sample collected from a subject administered with the MAP of the present invention. These methods can be used to evaluate the production of antibodies in a subject administered with the MAP of the present invention.
- the present invention can be applied to the production of monoclonal antibodies.
- monoclonal antibodies when producing monoclonal antibodies, experimental animals (eg, mice) are immunized with antigens, and when T cells and B cells have sufficiently reacted, spleen cells are taken out and fused with hybridomas.
- T cells and B cells when T cells and B cells have sufficiently reacted, spleen cells are taken out and fused with hybridomas.
- antibodies can be produced in a T cell-independent manner, and it becomes easy to obtain an antibody that recognizes a target antigen by ignoring T cells and activating only B cells.
- the antibody recognition site can also be freely designed based on the peptide sequence
- the conventional monoclonal antibody recognition site depends on the recognition of T cells and B cells in the immunized animal body. It is possible to obtain an antibody that recognizes this site.
- the present invention facilitates not only the development of therapeutic and preventive drugs, but also the acquisition of monoclonal antibodies necessary for research.
- a gene sequence encoding an antigen recognition site that is, a site including a complementarity determining region (CDR) of an antibody heavy chain or light chain, or the antibody
- CDR complementarity determining region
- Example 1 ⁇ Peptide sequence> Among the amino acid sequences of human, dog and mouse IgE CH3 regions, the sequence of a highly homologous site and a site protruding outward as a protein three-dimensional structure (aa293-304) was used as a synthetic peptide used in the experiment. . In particular, if there is IgE already bound to mast cells, the peptide used in MAP must be designed so that anti-IgE antibodies induced by MAP do not crosslink the IgE and induce mast cell degranulation. Don't be.
- B cell recognition peptide and MAP core peptide were synthesized using the Fmoc solid phase synthesis method. Specifically, Fmoc-His (Trt) -TrtA-PEG Resin 0.1 mmol was used as a solid phase carrier and synthesized according to the procedure shown in Table 2. The sequence of the B cell recognition peptide was N 3 -PEG-DWIEGETYQCRVTH-OH, and the peptide was extended from the C terminus toward the N terminus.
- Example 3 ⁇ Synthesis of MAP-peptide> The MAP core peptide and the B cell recognition peptide were combined using the Huisgen reaction. Specifically, the alkyne in the MAP core was activated with Cu (I), reacted with the azide group at the N-terminal of the B cell recognition peptide, and bound with triazole.
- MAP core peptide and B cell recognition peptide are dissolved in 8M aqueous urea solution.
- the mixing ratio is 1 mg (0.9 ⁇ mol) of MAP core peptide: 14 mg (7.2 ⁇ mol) of B cell recognition peptide, which is dissolved in 1.8 ml of 8M urea aqueous solution. This solution is referred to as a “peptide solution”.
- a copper sulfate pentahydrate aqueous solution and an ascorbic acid aqueous solution are prepared.
- a copper sulfate pentahydrate aqueous solution is prepared by dissolving 18 mg (72 ⁇ mol) of copper sulfate pentahydrate in 0.5 ml of distilled water (DW). This solution is referred to as “copper sulfate aqueous solution”.
- Ascorbic acid aqueous solution was prepared by adding 63 mg (358 ⁇ mol) of ascorbic acid to 0.5 ml of D.I. W. Prepare by dissolving in This solution is referred to as “ascorbic acid aqueous solution”.
- the Hüsgen reaction is a reaction in which alkyne and azide are combined using a monovalent copper ion as a catalyst, and the reaction product is stable and has almost no side reaction, and is attracting attention as a click chemistry.
- the outline of the Huisgen reaction is described below.
- the Cu + solution was prepared as in Step 2 above using copper sulfate pentahydrate aqueous solution and ascorbic acid, and used for the Huesgen reaction.
- Peptide solution (1.8 ml) and Cu + solution (0.2 ml) were mixed and allowed to react at room temperature for several hours to overnight.
- the desired product was purified and lyophilized by reverse phase HPLC using 0.1% TFA and ACN as eluents.
- Example 4 ⁇ Mouse administration experiment 1: Determination of the number of peptides that bind to MAP> This experiment was performed to select MAP-2, MAP-4, MAP-8, and MAP-16 having high antibody induction ability. Balb / c mice (female, 6 weeks of age) were used to group and administer MAP and saline (negative control) as described in Table 3.
- the experiment was conducted over 7 weeks (0 to 7 W) according to the schedule shown in FIG. 2A (W represents a week). During that time, MAP was administered 3 times (administration time: 0 W, 2 W, 6 W), and blood was collected 3 times (time of blood collection: 0 W, 1 W, 7 W).
- the antibody titer was measured using an ELISA method using canine IgE for immobilization. Specifically, dog IgE (Bethyl) was immobilized on an ELISA plate at a concentration of 0.1 ⁇ g / ml overnight at 4 ° C., and then mouse serum diluted 500-fold with a blocking buffer was added to react. I let you. Thereafter, the plate was washed, and biotin-labeled anti-mouse IgG donkey antibody (Rockland) was used for detection of mouse IgG, and biotin-labeled anti-mouse IgM goat antibody (Rockland) was used for detection of mouse IgM at a 5000-fold dilution.
- dog IgE Bethyl
- mouse serum diluted 500-fold with a blocking buffer was added to react. I let you. Thereafter, the plate was washed, and biotin-labeled anti-mouse IgG donkey antibody (Rockland) was used for detection of
- Streptavidin-conjugated ⁇ -galactosidase was added, 4-methyl Umbriferyl ⁇ -D-galactoside (4MU) was added as a fluorescent substrate, and the fluorescence intensity was finally measured with a fluorescence plate reader.
- the value at 0 W was 1, and the IgM value was displayed as a value of 1 W, and the IgG value was expressed as a ratio of 7 W.
- the administration schedule is as shown in FIG. 3A.
- Administration was performed at week 0 (0W) and week 2 (2W), blood was collected at 0W, 1W, and 3W, and IgM and IgG were measured as described above.
- the values of 0 W and 1 W were compared (IgM measurement), and the values of OW and 3 W were compared (IgG measurement).
- IgM measurement the values of 0 W and 1 W were compared
- IgG measurement the values of OW and 3 W were compared
- IgG production by MAP-4 and MAP-8 which are the MAPs of the present invention, is caused by administration of only the B cell epitope that the inventors desire to induce antibodies, and is caused by T cell non-intermediation. Therefore, it was predicted that B cells stimulated by MAP-4 or MAP-8 upon stimulation of non-specific (independent of T cell epitopes) interferon ⁇ would produce IgG, and the following experiment was conducted. .
- mice T cell-deficient mice
- FIG. 4A nude mice (8 weeks old, female) were administered with MAP-4 and a mouse interferon ⁇ preparation (Peprotech) at the same time, and only with MAP-4 administration and not with an interferon ⁇ preparation. IgG production was examined between the two.
- the interferon ⁇ preparation was administered intravenously three times at 6 hour intervals on the day of MAP-4 administration. Blood was collected before administration and every week after administration until 4 weeks later, and the changes in IgM and IgG antibody titers were examined.
- IgG against canine IgE in group 1 is the same as IgG against mouse IgE in the above experiment (ie, it is indeed a mouse IgE autoantibody)
- the IgG antibody titer against mouse IgE is then measured.
- a suppression test was carried out by adding canine IgE to the serum in advance.
- the serum used in this experiment was the serum that showed the highest antibody titer in the nude mouse experiment.
- mouse IgG the antibody titer of mouse IgG was measured by an ELISA method using mouse IgE for immobilization.
- dog IgE Bethyl
- mouse IgG was added to the same serum in advance, and then reacted with mouse IgG against mouse IgE. was measured.
- MAP-peptide induces autoantibodies for IgE through the above experiments.
- the target IgG can be produced only with a chemical compound having a MAP-peptide structure without involvement of T cells, and at the same time, IgG can be induced for foreign antigens other than autoantibodies. Is shown.
- the number of peptides effective for IgG induction in the MAP peptide could be determined from 4 to 8.
- Example 7 ⁇ Changes in IgE-specific IgE in sensitized dogs> Three beagle dogs were used, and 250 ⁇ g of Japanese leopard mite antigen (Greer) was subcutaneously administered twice a week with 25 mg of Alum (aluminum hydroxide) adjuvant. After an increase in IgE-specific IgE was observed (0w), 2 treated dogs (12-35 and 12-36) were intravenously injected with 1 mL of physiological saline containing 500 ⁇ g of MAP-8 as in Example 5. . As a negative control, 1 mL of physiological saline was intravenously administered to the remaining one (12-15).
- Alum aluminum hydroxide
- Example 8 ⁇ Examination of suppression effect of IgE rise in boosted condition by allergen> Using three beagle dogs (1 year old, 2 females, 1 male), 250 ⁇ g of a crude antigen of white mite mite (manufactured by Greer) was subcutaneously injected twice with 25 mg of alum adjuvant for allergen sensitization. After confirming that the IgE value against the white mite was sufficiently increased, MAP-8 dissolved in 1 ml of physiological saline was intravenously injected at 500 ⁇ g / head / dose 3 times every 2 weeks (administration groups 12-35 and 2 of 12-36). As the control group, the remaining one was injected with the same amount of physiological saline.
- the crude mite antigen was subcutaneously injected at 100 ⁇ g and allergen boosted (displayed in the graph, allergen administration).
- allergen administration On the 4th day after administration of the allergen, the same amount of MAP-8 was intravenously injected as before, and on the 5th and 13th days after the allergen administration, IgE values against mite mite were measured.
- the increase ratio of IgE with respect to white mite in the administration group was calculated by setting the measured value at the time of allergen administration to 1.0, and it was found that the increase in IgE value of the white mite in the administration group was weaker than that of the dog in the control group. Thus, it was found that administration of MAP-8 suppresses the increase in IgE even under allergen exposure. The results are shown in FIG.
- the present invention provides multiple alloantigen peptides having 4 to 8 B cell recognition peptides.
- the multiple alloantigen peptides of the present invention allow the production of antibodies that are class-switched in a T cell-independent manner in the body, even without an adjuvant. According to the present invention, it has been shown that antibodies can be produced even for subjects for which it has been difficult to induce antibodies.
- a multiple alloantigen peptide having a B cell recognition peptide derived from a peptide contained in a specific protein related to a disease can be an alternative method for an antibody drug.
- the present invention can easily produce autoantibodies and foreign antigens that have been impossible so far, and can be said to have extremely high industrial utility.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
(b)反応性官能基を有する複数の同種のB細胞認識ペプチドを用意する工程
(c)樹状コアの反応性官能基と上記の各B細胞認識ペプチドの反応性官能基を結合反応して多重抗原ペプチドを作製する工程
(d)多重抗原ペプチドを回収する工程
(15)上記反応性官能基を有する樹状コアが、下記の構造:
(18)以下の工程(b)~(d)をさらに含む、上記(17)に記載の方法。
(c)工程(b)で採取した生体試料から上記B細胞を選択する工程
(d)上記B細胞を培養して抗体を回収する工程
(19)上記(1)に記載の多重同種抗原ペプチドを投与された対象から採取した生体試料から、上記多重同種抗原ペプチドのB細胞認識ペプチドに結合する抗体をスクリーニングする方法。
(b’’)投与した対象から生体試料を採取し、アレルゲンを認識するIgG抗体を採取する工程
(22)上記(1)~(6)のいずれかに記載の多重同種抗原ペプチドを対象に投与して得られた当該対象の抗体産生B細胞より、抗体の抗原認識部位の遺伝子配列、または、抗体の抗原認識部位のアミノ酸配列を特定する方法。
1.多重同種抗原ペプチド
本発明は、第1の態様により、樹状コアとB細胞認識ペプチドとを含む多重同種抗原ペプチドであって、樹状コアの末端に直接またはスペーサーを介して結合された4~8個の同種のB細胞認識ペプチドを含み、かつ、T細胞エピトープ非存在下で生体内のB細胞を直接刺激してクラススイッチした抗体産生を誘導することを特徴とする、多重同種抗原ペプチドを提供する。
2.多重同種抗原ペプチドの製造
本発明は、第2の態様により、上記のMAPの製造方法であって、以下の工程(1)~(4):
(1)反応性官能基を有する樹状コアを用意する工程、
(2)反応性官能基を有する複数の同種のB細胞認識ペプチドを用意する工程、
(3)樹状コアの反応性官能基と上記の各B細胞認識ペプチドの反応性官能基を結合反応して多重抗原ペプチドを作製する工程、および
(4)多重抗原ペプチドを回収する工程
を含む方法を提供する。
3.抗体産生誘導剤
本発明はさらに、第3の態様により、上記のMAPを含む抗体産生誘導剤を提供する。本発明の抗体産生誘導剤は、T細胞非介在性でクラススイッチされた抗体産生を誘導する製剤である。
(a)自己抗体誘導用の抗体産生誘導剤
本発明の抗体産生誘導剤はT細胞非依存性であるため、抗体の産生がT細胞によって制限されている自己抗原に対する抗体(自己抗体)を人工的に誘導することが可能である。自己抗体を産生させることで、例えば健康維持に関係の無い分子を体内から排除することができる。多くの腫瘍性細胞は、正常細胞では微弱な発現である抗原を過剰に産生し、そのような抗原は血流に放出されるか細胞表面上に残る。これら腫瘍抗原に対する免疫反応は多様であり、しばしば腫瘍増殖の抑制には不十分である。本発明の抗体産生誘導剤は、腫瘍抗原に対する抗体を誘導することが可能である。
(b)これまでにワクチンを作ることができなかった疾患に対する抗体産生誘導剤
化学合成物によるワクチン製剤は、感染源である細菌やウイルスの構造が判明した時点でワクチン開発が可能であり、従来技術のように感染源の培養方法が確立してようやくワクチン製剤開発に進むものとはそのワクチン開発のスピード感が大きく異なる。このことは、本発明が従来技術では対応できなかった感染症や新興感染症に適したワクチン製剤を作製可能であることを示している。
(c)外来物質に対応できる抗体産生誘導剤
本発明は化学合成により外来物質に対しては容易に目的の抗体産生を誘導できる方法であるといえる。従来技術では抗体作製が困難な箇所にも計画的に人工的に抗体を誘導することが可能である。具体的には、インフルエンザウイルスに対して従来の方法では変異が起こり易い抗原性の高い箇所にのみ抗体を誘導するワクチンしかできなかったが、本発明によって変異が起こらない抗原性の低い箇所にも強力に抗体産生を誘導することが可能である。
[実施例1]
<ペプチド配列>
ヒト、イヌおよびマウスのIgEのCH3領域のアミノ酸配列のうち、相同性の高い部位で、かつタンパク質立体構造として外部に突出している部位(aa293-304)の配列を実験で使用する合成ペプチドとした。特に、肥満細胞にすでに結合しているIgEがあった場合、MAPで誘導した抗IgE抗体がそのIgEを架橋して肥満細胞の脱顆粒を誘導しないよう、MAPで使用するペプチドを設計しなければならない。そのため、今回、IgE受容体との結合部分のペプチドに焦点を当てて設計した。合成ペプチドの配列を表1に示す。ただし、実際に、以下の実験に使用した配列はヒトの配列である。ちなみに、これをイヌの配列とマウスの配列と比較した場合、下線を付したアミノ酸が異なる。マウスへ投与した場合のこれらアミノ酸の認識については、下線部アミノ酸部分はマウスにとって外来異物となり、その他はマウスの自己になる。また、303および304番目のアミノ酸(TおよびH)は、抗IgEヒト型抗体医薬であるオマリズマブの認識部位である。
[実施例2]
<B細胞認識ペプチドおよびMAPコアペプチドの合成>
B細胞認識ペプチドおよびMAPコアペプチドの具体的な合成方法は以下のとおりである。
[実施例3]
<MAP-ペプチドの合成>
MAPコアペプチドとB細胞認識ペプチドは、ヒュスゲン反応を利用し結合させた。具体的には、MAPコア中のアルキンをCu(I)で活性化しB細胞認識ペプチドN末端のアジド基と反応させトリアゾールにより結合させた。
(工程1)
MAPコアペプチドとB細胞認識ペプチドを8M尿素水溶液に溶解する。混合比は、MAPコアペプチド1mg(0.9μmol):B細胞認識ペプチド14mg(7.2μmol)であり、8M尿素水溶液1.8mlに溶解する。この溶液を「ペプチド溶液」と称する。
(工程2)
硫酸銅・5水和物水溶液とアスコルビン酸水溶液を調製する。
(工程3)
MAPコアペプチドとB細胞認識ペプチドとの結合を、ヒュスゲン反応を利用して行う。
[実施例4]
<マウスへの投与実験1:MAPに結合するペプチド数の決定>
MAP-2、MAP-4、MAP-8およびMAP-16のうち抗体誘導能の高いものを選択するためにこの実験を行った。Balb/cマウス(雌、6週齢)を用いて表3に記載のように群わけしてMAPおよび生理的食塩水(陰性対照)を投与した。
[実施例5]
<マウスへの投与実験2:MAP-4およびMAP-8の最適投与量の決定>
次にMAP-4およびMAP-8の投与量を変えて抗体誘導に最適な投与量を検討した本実験にはBalb/cマウス(雌、6週齢)を使用した。群わけは表4に記載のとおりである。これらMAPの一回投与量はマウス1匹あたり0.001μgから1μgまで設定し、群1~4はMAP-4、群5~8はMAP-8、そして群9は陰性対照として生理的食塩水を投与した。
[実施例6]
<ヌードマウスへの投与実験3:MAP-ペプチドだけによるIgG誘導の概念証明>
これまでT細胞非介在性抗原によってIgMは誘導されるものの、IgGへの抗体クラススイッチは起こらないとされてきた。それはIgGへのクラススイッチにはT細胞からのインターフェロンγ刺激を抗体産生B細胞が受け取ることが必要であり、そのためにはT細胞とB細胞の間での抗原情報(のやり取りT細胞エピトープの認識)が必要であった。すわわち、MAP-ペプチドによるIgG産生にはT細胞介在性の抗原特異的な反応が不可欠であった。このことから、これまでの知見によると、MAP-ペプチドを使ってT細胞介在性反応を起こすために、MAP-ペプチドのペプチド部分にはT細胞エピトープとB細胞エピトープを合わせたものが挿入されてきた(非特許文献1および非特許文献2)。さらにはT細胞に強制的に認識させるために、その作用を持つアジュバントとともに投与されてきた。
[実施例7]
<感作犬におけるコナヒョウヒダニ特異的IgEの変化>
ビーグル犬3頭を使用し、コナヒョウヒダニ抗原(Greer社)250μgをアラム(Alum;水酸化アルミニウム)アジュバント25mgとともに1週間間隔で2回皮下投与した。コナヒョウヒダニ特異的IgEの上昇を認めた後(0w)、治療実施犬2頭(12-35および12-36)には実施例5と同じMAP-8を500μg含む1mLの生理食塩水を静脈注射した。陰性対照として残りの1頭(12-15)に1mLの生理食塩水を静注した。MAP-8の投与によって抗IgE自己抗体が生じると考えられる2回目のMAP-8投与後、1週間目にコナヒョウヒダニIgEの低下が認められた。一方、陰性対照のイヌのコナヒョウヒダニIgEは低下しなかった。結果を図6に示す。なお、IgEは血中に一定濃度が存在するようマウス体内で調節されるため、翌週には治療実施犬においてもIgE量が増加した。このような場合は、MAP-8の複数回投与、又はMAP-8と同時にインターフェロンγ産生を上げる(もしくは、高める)ことなどにより、治療効果を改善することが期待できる。
[実施例8]
<アレルゲンによるブースト状態におけるIgE上昇の抑制効果の検討>
3頭のビーグル犬(1歳、メス2頭、オス1頭)を用いて、コナヒョウヒダニの粗抗原(Greer社製)250μgをアラムアジュバント25mgとともに2回皮下注射し、アレルゲン感作した。コナヒョウヒダニに対するIgE値が十分に上昇したことを確認した後、2週間毎に3回、生理的食塩水1mlに溶解したMAP-8を500μg/頭/回で静脈注射した(投与群12-35および12-36の2頭)。対照群として残りの1頭には同量の生理的食塩水を注射した。その後、定期的にコナヒョウヒダニに対するIgE値を測定したが、値に変化が見られなかったため、8週間後にコナヒョウヒダニ粗抗原を100μgで皮下注射し、アレルゲンブーストした(グラフ中表示、アレルゲン投与)。このアレルゲン投与後4日目にこれまでと同量のMAP-8を静注し、アレルゲン投与後5日および13日目にコナヒョウヒダニに対するIgE値を測定した。その結果、アレルゲン投与時の測定値を1.0としてコナヒョウヒダニに対するIgEの上昇比を算出したところ、投与群のコナヒョウヒダニのIgE値の上昇は対照群の犬に比較して弱いことがわかった。これによって、MAP-8の投与によりアレルゲン暴露下においてもそのIgE上昇が抑制されることがわかった。結果を図7に示す。
Claims (15)
- 樹状コアとB細胞認識ペプチドとを含む多重同種抗原ペプチドであって、樹状コアの末端に直接またはスペーサーを介して結合された4~8個の同種のB細胞認識ペプチドを含み、かつ、T細胞エピトープ非存在下で生体内のB細胞を直接刺激してクラススイッチした抗体産生を誘導することを特徴とする、多重同種抗原ペプチド。
- 樹状コアが、リジン残基を含む、請求項1に記載の多重同種抗原ペプチド。
- 樹状コアが、システイン残基をさらに含む、請求項2に記載の多重同種抗原ペプチド。
- B細胞認識ペプチドが、7~50アミノ酸残基からなるペプチドである、請求項1~3のいずれか1項に記載の多重同種抗原ペプチド。
- B細胞認識ペプチドが、自己抗原である、請求項1~4のいずれか1項に記載の多重同種抗原ペプチド。
- 自己抗原が、IgE由来の抗原である、請求項5に記載の多重同種抗原ペプチド。
- 請求項1~6のいずれか1項に記載の多重同種抗原ペプチドを有効成分として含有する、抗体産生誘導剤。
- インターフェロンγおよび/またはインターフェロンγ産生能を有するアジュバントをさらに含む、請求項7に記載の抗体産生誘導剤。
- 抗体がIgG抗体である、請求項7または8に記載の抗体産生誘導剤。
- ワクチンである、請求項7~9のいずれか1項に記載の抗体産生誘導剤。
- 疾患の治療または予防のために使用される、請求項7~10のいずれか1項に記載の抗体産生誘導剤。
- 疾患が、アレルギー性疾患、癌、骨疾患、加齢黄斑変性症、多発性硬化症、尋常性乾癬および感染症からなる群から選択される、請求項11に記載の抗体産生誘導剤。
- 請求項7~12のいずれか1項に記載の抗体産生誘導剤を含む医薬組成物。
- 請求項1~6のいずれか1項に記載の多重同種抗原ペプチドの製造方法であって、以下の工程(a)~(d)を含む方法。
(a)反応性官能基を有する樹状コアを用意する工程
(b)反応性官能基を有する複数の同種のB細胞認識ペプチドを用意する工程
(c)樹状コアの反応性官能基と上記の各B細胞認識ペプチドの反応性官能基を結合反応して多重抗原ペプチドを作製する工程
(d)多重抗原ペプチドを回収する工程
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2959477A CA2959477C (en) | 2014-06-11 | 2015-06-11 | Multiplexed same type-antigenic peptide |
JP2016527857A JP6739702B2 (ja) | 2014-06-11 | 2015-06-11 | 多重同種抗原ペプチド |
US15/317,693 US10428112B2 (en) | 2014-06-11 | 2015-06-11 | Multiplexed same type-antigenic peptide |
EP15806911.2A EP3156423A4 (en) | 2014-06-11 | 2015-06-11 | Multiplex alloantigenic peptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-120999 | 2014-06-11 | ||
JP2014120999 | 2014-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015190555A1 true WO2015190555A1 (ja) | 2015-12-17 |
Family
ID=54833642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/066865 WO2015190555A1 (ja) | 2014-06-11 | 2015-06-11 | 多重同種抗原ペプチド |
Country Status (5)
Country | Link |
---|---|
US (1) | US10428112B2 (ja) |
EP (1) | EP3156423A4 (ja) |
JP (1) | JP6739702B2 (ja) |
CA (1) | CA2959477C (ja) |
WO (1) | WO2015190555A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018052837A (ja) * | 2016-09-27 | 2018-04-05 | 国立研究開発法人理化学研究所 | エボラウイルスワクチン |
JP2018070571A (ja) * | 2016-11-04 | 2018-05-10 | 国立研究開発法人理化学研究所 | 免疫誘導剤 |
WO2020059832A1 (ja) | 2018-09-21 | 2020-03-26 | 国立研究開発法人理化学研究所 | IgE抗体産生B細胞の膜結合型IgE抗体に特異的に結合する抗IgE抗体とこれを用いたアレルギー症状の診断および治療方法 |
WO2021235553A1 (ja) | 2020-05-22 | 2021-11-25 | 国立研究開発法人理化学研究所 | コロナウイルスに対する多重抗原ペプチドおよびこれを含む免疫賦活化組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000502995A (ja) * | 1995-12-06 | 2000-03-14 | ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン | Bリンパ球による抗体放出を刺激する組成物および方法 |
JP2002281984A (ja) * | 2000-08-30 | 2002-10-02 | Pfizer Prod Inc | 抗IgEワクチン |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022343A1 (en) | 1992-05-01 | 1993-11-11 | The Rockfeller University | Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom |
AU7193501A (en) | 2000-07-10 | 2002-01-21 | Us Health | Multiple antigenic peptides immunogenic against streptococcus pneumoniae |
WO2004087864A2 (en) | 2002-10-08 | 2004-10-14 | Dow Agrosciences Llc | Amended recombinant cells (arcs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants |
TWI357414B (en) * | 2003-12-17 | 2012-02-01 | Wyeth Llc | Aβ immunogenic peptide carrier conjugates and meth |
CN101503460A (zh) | 2009-03-12 | 2009-08-12 | 上海交通大学 | IgE抗原性序列及分支多聚抗原肽的制备方法 |
-
2015
- 2015-06-11 US US15/317,693 patent/US10428112B2/en active Active
- 2015-06-11 CA CA2959477A patent/CA2959477C/en active Active
- 2015-06-11 EP EP15806911.2A patent/EP3156423A4/en active Pending
- 2015-06-11 JP JP2016527857A patent/JP6739702B2/ja active Active
- 2015-06-11 WO PCT/JP2015/066865 patent/WO2015190555A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000502995A (ja) * | 1995-12-06 | 2000-03-14 | ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン | Bリンパ球による抗体放出を刺激する組成物および方法 |
JP2002281984A (ja) * | 2000-08-30 | 2002-10-02 | Pfizer Prod Inc | 抗IgEワクチン |
Non-Patent Citations (10)
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018052837A (ja) * | 2016-09-27 | 2018-04-05 | 国立研究開発法人理化学研究所 | エボラウイルスワクチン |
WO2018062217A1 (ja) * | 2016-09-27 | 2018-04-05 | 国立研究開発法人理化学研究所 | エボラウイルスワクチン |
JP2018070571A (ja) * | 2016-11-04 | 2018-05-10 | 国立研究開発法人理化学研究所 | 免疫誘導剤 |
WO2018084247A1 (ja) * | 2016-11-04 | 2018-05-11 | 国立研究開発法人理化学研究所 | 免疫誘導剤 |
WO2020059832A1 (ja) | 2018-09-21 | 2020-03-26 | 国立研究開発法人理化学研究所 | IgE抗体産生B細胞の膜結合型IgE抗体に特異的に結合する抗IgE抗体とこれを用いたアレルギー症状の診断および治療方法 |
JPWO2020059832A1 (ja) * | 2018-09-21 | 2021-09-30 | 国立研究開発法人理化学研究所 | IgE抗体産生B細胞の膜結合型IgE抗体に特異的に結合する抗IgE抗体とこれを用いたアレルギー症状の診断および治療方法 |
WO2021235553A1 (ja) | 2020-05-22 | 2021-11-25 | 国立研究開発法人理化学研究所 | コロナウイルスに対する多重抗原ペプチドおよびこれを含む免疫賦活化組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2959477C (en) | 2020-10-20 |
US20170158738A1 (en) | 2017-06-08 |
EP3156423A4 (en) | 2018-04-11 |
JPWO2015190555A1 (ja) | 2017-04-20 |
US10428112B2 (en) | 2019-10-01 |
EP3156423A1 (en) | 2017-04-19 |
JP6739702B2 (ja) | 2020-08-12 |
CA2959477A1 (en) | 2015-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Klinman et al. | DNA vaccines: safety and efficacy issues | |
JP6466327B2 (ja) | 免疫調節ワクチン | |
JP7250032B2 (ja) | アトピー性皮膚炎の治療及び/または予防のためのil-31のペプチド免疫原ならびにその製剤 | |
WO2015190555A1 (ja) | 多重同種抗原ペプチド | |
RU2664197C2 (ru) | Иммуногенная композиция, включающая ее вакцина, набор для приготовления вышеуказанной композиции и способ лечения заболеваний, связанных с патологией секреции гастрина | |
US20230218748A1 (en) | Artificial promiscuous t helper cell epitopes as immune stimulators for synthetic peptide immunogens | |
JP2005530723A (ja) | 新規ペプチド及び治療を目的とするその利用 | |
KR101215780B1 (ko) | 동물의 면역 방법, 면역용 조성물, 항체의 제조 방법,하이브리도마의 제조 방법 및 모노클로날 항체의 제조 방법 | |
CN111565801B (zh) | 用于IgE介导过敏性疾病治疗的靶向膜结合型IgE的肽免疫原及其剂型 | |
WO2024111633A1 (ja) | タンパク質に対する抗体の作製 | |
CN118184783A (zh) | Hla-g抗体及其制备方法和用途 | |
CN118146376A (zh) | Hla-g抗体及其制备方法和用途 | |
JP5164161B2 (ja) | インビトロ免疫法 | |
Hanly et al. | Information Resources for Adjuvants and Antibody Production: Comparisons and Alternative Technologies | |
JP2010075169A (ja) | 抗体産生細胞の誘導又は活性化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15806911 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016527857 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015806911 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015806911 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15317693 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2959477 Country of ref document: CA |